ARD's Impact Factor Save

Annals of the Rheumatic Diseases (ARD) is the official journal of EULAR –The European Alliance of Associations for Rheumatology. An international peer-reviewed publication committed to promoting the highest standards of scientific exchange and education. New Journal Impact Factors released for 2024 confirm ARD’s position as a leader in the field of rheumatology and musculoskeletal diseases (RMD), with EULAR Recommendations and original research driving the reach. 

The 2024 Impact Factor for ARD is 20.6 – an increase from 20.3 in 2023. This retains the journal’s position as second of 58 titles in the rheumatology category and confirms its status as the top-ranking journal for the publication of original research in both the basic and clinical fields. In parallel, ARD continues to be the number one journal of 76 rheumatology titles according to CiteScore, another metric, a position it holds now for many years.

The influence of ARD is not only demonstrated by the fact that articles published in the journal are cited in a wide variety of other journals, but also by the more than 50,000 citations of ARD publications last year – a clear sign of the wide reach and recognition of the journal.

Josef Smolen – Editor-in-Chief at ARD and Emeritus Professor of Medicine at Medical University of Vienna, Austria – said “Over the years it has been a pleasure and honour to work with a terrific group of associate editors, editorial board members and reviewers who all have supported the journal tremendously. My sincere gratitude also goes to the authors of the many papers we publish whose work contributes so importantly to the visibility of the Annals of the Rheumatic Diseases. The editorial policy will continue to strive for highest quality and novelty to provide the best information for the world’s rheumatological community and to advance diagnostic and therapeutic options for our patients.”

A journal’s Impact Factor is calculated by taking the number of citations across the full calendar year to citable articles published in the previous two years, and dividing that by the number of citable articles published in those two years.

CiteScore is a separate journal-level metric based on Scopus data and calculated by dividing the number of citations across four full calendar years by the number of all articles published in the same four year period. The 2024 CiteScore for ARD is 33.2.

ARD is published by Elsevier. For anyone interested in submitting their work, ARD considers original research, reviews, recommendations and criteria, as well as editorials, letters, and viewpoints. All information and guidance for authors can be found here.

About EULAR

EULAR is the European umbrella organisation representing scientific societies, health professional associations and organisations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.